PharmacoMRI of Parkinson Disease

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Treatments: Carbidopa; Carbidopa, levodopa drug combination; Levodopa

Criteria

Inclusion Criteria:

• Idiopathic Parkinson's Disease (PD)

• Older than 30 years of age at the time of diagnosis

• Hoehn and Yahr stage greater than or equal to 2.5

• PD duration greater than 3 years

• Stable regimen of PD medications for at least 2 weeks prior to imaging

• PD medications include carbidopa-levodopa

Exclusion Criteria:

• Patients with a diagnosis of other neurodegenerative conditions

• Patients unwilling or unable to give informed consent

• Contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo MRI scan